Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

HemoGenyx shares soar after news of first solid data on leukemia treatment

The company said first data results have shown that its lead product, CDX bi-specific antibodies, is capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro
laboratory
HemoGenyx is confident that it should be able to demonstrate that CDX bi-specific antibodies are effective in the treatment of AML

HemoGenyx Pharmaceuticals PLC (LON:HEMO) shares leapt 120% higher on Monday after it confirmed an earlier enigmatic tweet by saying it is "excited" by first data results from its lead product for the treatment of leukaemia.

All the tweet had said was “A serious breakthrough in the lab”, but it sent the AIM-listed firm's shares soaring first thing, prompting the group to release a regulatory news statement announcing that it has filed a provisional patent application relating to the development of a new type of humanised mice with a chimeric mouse-blood system that can be used to advance product development, as well as for other disease modelling and drug development.

READ: Hemogenyx happy with progress and recent collaborations

The company also noted that first data results have shown that its lead product, CDX bi-specific antibodies, are capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro.

Using these new humanised mice, HemoGenyx said it is confident that it should be able to demonstrate that CDX bi-specific antibodies are effective in the treatment of AML.

Dr Vladislav Sandler, CEO and co-founder of the company, commented: "We are hugely excited by the first solid data that we've received testing the efficacy of CDX antibodies against Acute Myelogenous Leukemia.

"The results which show that they can attack and eliminate AML cells is a true breakthrough and a significant development in our process of developing CDX to become a universally available conditioning product for patients undergoing bone marrow transplants as a treatment for serious blood diseases."

He continued: “In addition, the new type of humanised mice opens the door to extending our work into other disease models and specific drug development which we expect to be of great interest to large biopharmaceutical companies and could form the basis of a number of significant future collaborations.”   

In late afternoon trading, HemoGenyx's shares were up 123% at 4.75p. The company added that it regrets the "premature disclosure" of the tweet which it said "is not in accordance with the Company's policies on the release of information".

View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

Video
January 11 2018

Related Articles

Blood cells
October 12 2017
Current standard of care treatment involves chemotherapy and radiotherapy and ultimately, in recurring cases, a bone marrow transplant
Internet TV specialsit Falcon Media House transformed and ready to start generating revenues
August 25 2017
It has gone from a cash shell to fully fledged online TV company plugged into a massive market in a year and half
cannabis plant
February 01 2018
Today, the group closed the US$18mln acquisition of Citiva Medical and Citiva USA

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use